Precision Diagnostics in Primary Sjögren’s Syndrome: Advances in Biomarkers, Epigenetic Markers, Immune Pathways, and Clinical Translation
Frontiers in Bioscience-Landmark · 24.03.2026 · 31 (3)
DOI: 10.31083/fbl44757 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 24.03.2026. Verfasst von Thao Thi Do und 7 weiteren Autor:innen. Beteiligte Einrichtung: Oral Diagnosis and Periodontology Department, Faculty of Odonto-Stomatology, Can Tho University of Medicine and Pharmacy, 900000 Can Tho, Vietnam. Hauptthemen laut MEDLINE: Sjogren's Syndrome, Biomarkers, Epigenesis, Genetic, Precision Medicine. Die Arbeit nennt 275 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease defined by exocrine gland infiltration and systemic involvement. The management of pSS is hampered by three persistent challenges: seronegativity, heterogeneity, and delayed diagnosis. Up to one-third of patients lack anti-Sjögren’s-syndrome-related antigen A/B (SSA/SSB) autoantibodies, contributing to misclassification and delayed recognition. Recent studies have expanded the autoantibody repertoire, identifying novel targets such as anti-D-aminoacyl-tRNA deacylase 2 (DTD2), anti-retroelement silencing factor-1 (RESF1), and anti-calreticulin (CALR), as well as multiplex panels including anti-salivary protein-1 (SP-1), anti-parotid secretory protein (PSP), and anti-carbonic anhydrase VI (CA6). These can detect disease before conventional seroconversion, thus offering diagnostic value for seronegative cases. The greatest challenge remains early detection, as the current reliance on biopsy and late-appearing serologies overlooks subclinical disease. In this context, non-invasive fluid biomarkers are transformative, with salivary and tear fluid proteomics (β2-microglobulin, clusterin, matrix metalloproteinase-9), exosomal micro ribonucleic acid (miRNAs), and metabolomic fingerprints providing sensitive indicators of glandular dysfunction and immune activation. When combined with machine learning, integrated multi-omics panels can achieve diagnostic accuracies comparable to biopsy while enabling prognostic stratification. Emerging approaches also leverage artificial intelligence (AI) to refine biomarker discovery and clinical translation. AI-assisted ultrasonography enables reproducible quantification of glandular inflammation, while the application of integrative AI models to multi-omics datasets can identify biomarker signatures with superior predictive accuracy. Such tools have the potential to accelerate early diagnosis, automate risk prediction, and guide precision therapeutics in real time. The future use of biomarker panels in clinical practice should reduce the time to diagnosis, thereby facilitating the anticipation of risk and the provision of therapy based on the underlying cause. In this review, we describe how pSS exemplifies some of the problems inherent in contemporary autoimmunity. This multifaceted and diverse condition is now well-positioned to benefit from integrative, biomarker-driven methodologies, which should lead to improved patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oral Diagnosis and Periodontology Department, Faculty of Odonto-Stomatology, Can Tho University of Medicine and Pharmacy, 900000 Can Tho, Vietnam.
- Department of Physiology, Faculty of Medicine, Can Tho University of Medicine and Pharmacy, 900000 Can Tho, Vietnam.
- Faculty of Odonto-Stomatology, College of Health Sciences, Nam Can Tho University, 900000 Can Tho, Vietnam.
- Department and Institute of Physiology, College of Medicine, National Yang Ming Chiao Tung University, 112304 Taipei, Taiwan.
Zitieren
APA
Do, T. T., Nguyen, V. T., Duong, K. T. T., Truong, H. G., Le, D. N. T., Le, Q. M. M., Trinh, T. N., & Nguyen, T. H. (2026). Precision Diagnostics in Primary Sjögren’s Syndrome: Advances in Biomarkers, Epigenetic Markers, Immune Pathways, and Clinical Translation. Frontiers in Bioscience-Landmark, 31(3). https://doi.org/10.31083/fbl44757
Vancouver
Do TT, Nguyen VT, Duong KTT, Truong HG, Le DNT, Le QMM, et al. Precision Diagnostics in Primary Sjögren’s Syndrome: Advances in Biomarkers, Epigenetic Markers, Immune Pathways, and Clinical Translation. Frontiers in Bioscience-Landmark. 2026;31(3). doi:10.31083/fbl44757
BibTeX
@article{Do2026,
author = {Do, Thao Thi and Nguyen, Vy Thuy and Duong, Kim Tran Thien and Truong, Huy Gia and Le, Duong Nguyen Thuy and Le, Quan Minh Mai and Trinh, Thu Ngoc and Nguyen, Tin Hoang},
title = {Precision Diagnostics in Primary Sjögren’s Syndrome: Advances in Biomarkers, Epigenetic Markers, Immune Pathways, and Clinical Translation},
journal = {Frontiers in Bioscience-Landmark},
year = {2026},
volume = {31},
number = {3},
doi = {10.31083/fbl44757}
}
EUVIMED